Tag: Alder Biopharmaceuticals
May 6, 2019
Alder BioPharmaceuticals Presents New Data from Clinical Trials
Alder BioPharmaceuticals (NASDAQ:ALDR) has released new data showing consistency of early migraine prevention benefit in four clinical trials with eptinezumab.... October 23, 2018
Alder BioPharmaceuticals Announces Positive Results From Pharmacokinetic Comparability Study for Eptinezumab
Alder Biopharmaceuticals (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced positive... May 9, 2018
Alder BioPharmaceuticals Reports First Quarter 2018 Financial and Operating Results
Alder BioPharmaceuticals (NASDAQ:ALDR) a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today provided a... April 25, 2018
Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine
Alder BioPharmaceuticals (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new... April 24, 2018
Alder BioPharmaceuticals Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine
Alder BioPharmaceuticals (NASDAQ:ALDR) a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new... February 26, 2018
Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
Alder BioPharmaceuticals (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, provided a corporate... January 29, 2018